Ethical Considerations Regarding Psychedelics for Clinical Pain Research DOI Creative Commons
Christopher L. Robinson,

Matthew Slitzky,

Michael E Schatman

et al.

Journal of Pain Research, Journal Year: 2024, Volume and Issue: Volume 17, P. 4357 - 4364

Published: Dec. 1, 2024

Psychedelics, substances with a long history of cultural and medicinal use, are experiencing resurgence in clinical research, particularly psychiatry. Despite their classification as Schedule I drugs, recent studies suggest therapeutic potential, treating refractory depression. With chronic pain representing major health concern few non-opioid treatment options available, psychedelics being explored alternative modalities. The National Institutes Health (NIH) now funds psychedelic marking shift from previous decades limited funding. However, ethical considerations loom large. Vulnerable populations, such those that impairs autonomy, require careful consideration by researchers risks benefits. Additionally, interested entities must navigate complex regulatory landscapes involving the United States Food Drug Administration (FDA) Enforcement (DEA) when considering pursuing possible research. Furthermore, transparent collaboration among stakeholders-patients, researchers, bodies-is crucial for participant safety successful Although number approaches can be taken, we posit stakeholders consider utilizing principal-based research ethics, comprised principles beneficence, justice, nonmaleficence, to guide process. Ultimately, balancing promise integrity is paramount. Careful planning, collaboration, adherence increase likelihood management progresses responsibly, offering hope patients while safeguarding well-being.

Language: Английский

The intensity of the psychedelic experience is reliably associated with clinical improvements: a systematic review and meta-analysis DOI
Bruno Roméo, E. Kervadec, Baptiste Fauvel

et al.

Neuroscience & Biobehavioral Reviews, Journal Year: 2025, Volume and Issue: 172, P. 106086 - 106086

Published: March 1, 2025

Language: Английский

Citations

1
Patterns of Internalizing Problems, Substance Use and Cognitive Flexibility Before and After Naturalistic Psilocybin Use: A Repeated Measures Latent Profile Analysis DOI
Jérémie Richard,

Jeremy Scott,

Sandeep M. Nayak

et al.

International Journal of Mental Health and Addiction, Journal Year: 2025, Volume and Issue: unknown

Published: April 24, 2025

Language: Английский

Citations

0
Psychedelics: A review of their effects on recalled aversive memories and fear/anxiety expression in rodents DOI
Isabel Werle, Leandro J. Bertoglio

Neuroscience & Biobehavioral Reviews, Journal Year: 2024, Volume and Issue: unknown, P. 105899 - 105899

Published: Sept. 1, 2024

Language: Английский

Citations

3
Considering distinct positive emotions in psychedelic science DOI
Sean P. Goldy,

Peter S. Hendricks,

Dacher Keltner

et al.

International Review of Psychiatry, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 12

Published: Sept. 2, 2024

In this review, we discuss psychedelics' acute subjective and persisting therapeutic effects, outline the science of positive emotions, highlight value in considering distinct emotions psychedelic science. Psychedelics produce a wide variety effects (i.e. 'trip'), including affective states such as awe joy. However, despite rich literature on their different correlates sequelae, remain understudied. Insofar may play role downstream (e.g. decreased depression, anxiety, substance misuse), experiences has potential to yield more precise statements about psychedelic-related processes outcomes. We propose here that understanding within context could help elucidate connection between

Language: Английский

Citations

1
Ethical Considerations Regarding Psychedelics for Clinical Pain Research DOI Creative Commons
Christopher L. Robinson,

Matthew Slitzky,

Michael E Schatman

et al.

Journal of Pain Research, Journal Year: 2024, Volume and Issue: Volume 17, P. 4357 - 4364

Published: Dec. 1, 2024

Psychedelics, substances with a long history of cultural and medicinal use, are experiencing resurgence in clinical research, particularly psychiatry. Despite their classification as Schedule I drugs, recent studies suggest therapeutic potential, treating refractory depression. With chronic pain representing major health concern few non-opioid treatment options available, psychedelics being explored alternative modalities. The National Institutes Health (NIH) now funds psychedelic marking shift from previous decades limited funding. However, ethical considerations loom large. Vulnerable populations, such those that impairs autonomy, require careful consideration by researchers risks benefits. Additionally, interested entities must navigate complex regulatory landscapes involving the United States Food Drug Administration (FDA) Enforcement (DEA) when considering pursuing possible research. Furthermore, transparent collaboration among stakeholders-patients, researchers, bodies-is crucial for participant safety successful Although number approaches can be taken, we posit stakeholders consider utilizing principal-based research ethics, comprised principles beneficence, justice, nonmaleficence, to guide process. Ultimately, balancing promise integrity is paramount. Careful planning, collaboration, adherence increase likelihood management progresses responsibly, offering hope patients while safeguarding well-being.

Language: Английский

Citations

1